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OBJECTIVES This study was designed to investigate the appropriateness and complications of the use of
spironolactone for heart failure (HF) in clinical practice.
BACKGROUND Spironolactone was reported by one prospective randomized trial to decrease morbidity and
mortality in patients with New York Heart Association (NYHA) class III and IV HF. With
this report (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a
marked increase in widespread use of spironolactone in patients with HF. Long-term
outcome data with respect to safety and utilization of this medication in HF are not available.
METHODS To investigate the use of spironolactone for HF in a clinical setting, we analyzed the
application of the RALES trial protocol to the care of 104 patients, whom we identified as
being started on spironolactone for HF after prerelease of the RALES trial.
RESULTS We found broader use, less intensive follow-up, and increased complications with spirono-
lactone treatment compared with the RALES trial. Cardiologists provided more appropriate
care than did primary care providers.
CONCLUSIONS These data suggest that spironolactone is being used widely in HF without consideration of
the NYHA class and ejection fraction, and without optimization of background treatment
with angiotensin-converting enzyme inhibitors and beta-blockers. Clinical follow-up does
not adhere to the RALES trial guidelines, resulting in higher complications. We conclude
that long-term studies with further safety and efficacy data are needed. (J Am Coll Cardiol
2003;41:211–4) © 2003 by the American College of Cardiology Foundation
Spironolactone has been reported to reduce morbidity and
mortality in patients with severe heart failure (HF) by a
single, prospective, randomized large-scale trial, the Ran-
domized Spironolactone Evaluation Study (RALES) (1).
Patients enrolled in the RALES trial were strictly limited to
those with advanced HF, normal serum potassium values,
and normal or only mildly elevated serum creatinine levels.
Moreover, in this study, spironolactone was used at very low
doses, far less than the customary doses used for cirrhosis or
hypertension (1).
See page 215
Spironolactone is a familiar diuretic for the primary care
physician—easy to initiate, simple to titrate, and very
reasonably priced (2). In contrast, though supported by a
large body of literature, the initiation, titration, and moni-
toring of angiotensin-converting enzyme inhibitors and
beta-blockers in HF can be difficult and time consuming
(3,4). With the report of the RALES trial, we noted
widespread use of spironolactone in patients with HF.
Considering the difference in patients enrolled in trials and
in clinical practice (5), we decided to investigate the appro-
priateness and complications of the use of spironolactone for
HF in clinical practice.
METHODS
Study cohort and protocol. Of the 377 patients with new
prescriptions for spironolactone after August 1, 1999, 110
were identified to be initiated for HF and constituted the
study cohort. The date was chosen after the prerelease of the
RALES trial on July 19, 1999, and subsequent media
publicity (6). Retrospective medical record reviews were
performed on all cohort patients. Inclusion criteria included
patients initiated on spironolactone for HF between August
1, 1999, and January 1, 2000, and consent of the primary
care providers for medical record review. Exclusion criteria
included patients with chronic liver disease, portal hyper-
tension, use of spironolactone for hypertension, or edema
without HF. Patient records were reviewed for 12 months
from the date of spironolactone initiation. Six patients were
excluded because no follow-up data were available.
Study objectives. Primary objectives were to 1) Determine
if patient selection adhered to the RALES criteria, which
included: a) New York Heart Association (NYHA) class IV
HF within six months; b) NYHA class III or IV HF at the
time of enrollment; c) left ventricular ejection fraction
(LVEF) 35% within six months; and d) exclusion of
patients with a serum creatinine 2.5 mg/dl or a serum
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potassium 5 mmol/l. 2) Determine whether management
followed the RALES trial criteria, which included: a)
dosing of spironolactone at 25 to 50 mg/day; b) laboratory
and clinic follow-up at four weeks and at three and six
months; c) appropriate use of angiotensin-converting en-
zyme inhibitors and beta-blockers; d) discontinuation of
potassium-sparing diuretics and potassium supplements,
unless potassium was 3.5 mmol/l; e) holding spironolac-
tone for hyperkalemia or creatinine 4 mg/dl. 3) Deter-
mine the incidence of the complications following spirono-
lactone use, prospectively defined as development of the
following: a) hyperkalemia with serum potassium 5.2
mEq/l or serious hyperkalemia 6.0 mEq/l; b) renal insuf-
ficiency with serum creatinine 2.0 mg/dl; and c) hypona-
tremia with serum sodium 135 mEq/l.
Secondary objectives were to determine 1) adverse events
related to hyperkalemia, such as temporary pacemaker
insertion for hemodynamically unstable bradyarrhythmia; 2)
incidence of hypotension, defined as drop in systolic blood
pressure (SBP) 15% compared with baseline and a SBP
90 mm Hg following spironolactone therapy; and 3)
correlation between appropriate management index and
specialization and training level of the providers.
This study was approved by the Baylor College of
Medicine and VA Medical Center Institutional Review
Board.
Statistical analysis. All data were expressed as mean 
SEM. The appropriate management index was calculated as
the weighed cumulative effect of use of angiotensin-
converting enzyme inhibitors, indicated NYHA or LVEF
selection, and indicated lab and clinic follow-up for spirono-
lactone use. Correlations were assessed by Spearman rank
test (Sigmastat, SPSS).
RESULTS
Patient demographics. Table 1 shows the baseline char-
acteristics of patients in our cohort in comparison with the
RALES trial. All of our patients were men, reflecting the
Veterans Affairs Medical Center population. Baseline char-
acteristics of age, LVEF, blood pressure (BP), and etiology
of HF were similar to those in the RALES trial.
Patient selection and follow-up. As shown in Table 2,
though almost all of the patients in the RALES trial were in
NYHA class III-IV HF, 9% of our patients had docu-
mented NYHA class I to II at baseline and only 25.6% had
the appropriate, documented NYHA class of III to IV. A
total of 65.4% of our patients did not have any classification
of NYHA before or after spironolactone initiation. Though
the mean LVEF was similar to the RALES trial, only
54.8% of the cohort patients had documented LVEF of
35% before beginning spironolactone.
Overall, most patients were on optimal background
therapy for HF: 80% were on angiotensin-converting en-
zyme inhibitors, 5% were on angiotensin receptor blockers,
and 3% were on hydralazine and isosorbide combination.
The mean daily doses of angiotensin-converting enzyme
inhibitors were much higher than in the RALES trial, but
closer to the target doses used in other studies and recom-
Table 1. Patient Demographics
Study Cohort
(n  104)
RALES trial
(n  822)
Age (yrs) 66.2  10 66  12
Male gender (%) 100 73
BP
Systolic 127  25 123  21
Diastolic 72  13 75  12
LVEF (%) 27.2  14.7 25.6  6.7
Cause of HF (% ischemic) 55.8 55
Data  SD.
BP  blood pressure; HF  heart failure; LVEF  left ventricular ejection
fraction; RALES  Randomized Spironolactone Evaluation Study.
Table 2. Patient Selection and Follow-Up
Study
Cohort
(n  104)
RALES
Trial
(n  822)
NYHA (% patients)
I 4.5 0
II 4.5 0.5
III 15.3 72
IV 10.3 27
Undocumented 65.4 0
% Patients with LVEF  35 54.8 100
Medications (% patients)
Loop diuretics 90.4 100
ACE inhibitors 79.8 95
Digitalis 55.7 75
Potassium supplements 40.4 29
Beta-blockers 34.6 11
Mean dose of ACE inhibitors
Captopril (mg/day) 120  12 63.4
Lisinopril (mg/day) 23  2 15.5
Mean dose of beta-blockers
Metoprolol (mg/day) 72.3  10 not reported
Mean dose of spironolactone
(mg/day)
40.7  3.1 26
% Patients continued on
potassium supplements
40.4 29
% Patients with renal
insufficiency at baseline
30.7 excluded
% Patients with diabetes
mellitus
46.2 not reported
ACE  angiotensin-converting enzyme; NYHA  New York Heart Association;
other abbreviations as in Table 1.
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
BP  blood pressure
HF  heart failure
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RALES  Randomized Spironolactone Evaluation
Study
SBP  systolic blood pressure
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mended by the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines (7). The mean
daily dose of spironolactone in our cohort (40.7  3.1 mg)
was also much higher than the dose used in the RALES
trial (26 mg). Thirty-five percent of our patients were on
beta-blockers and 40% of the patients were continued on
potassium supplements despite absence of hypokalemia. At
baseline, 31% of our patients had renal insufficiency and
46% had diabetes mellitus. Only 38% of our patients had
appropriate laboratory and 34% appropriate clinical follow-
up.
Adverse events. Twenty-four percent (n  25) of our
patients developed hyperkalemia (levels 5.2, normal po-
tassium values at our laboratory: 3.5–5.1 mEq/l). Twelve
percent (n  12) developed serious hyperkalemia (levels 6
mEq/l), compared with only 2% reported in the RALES
trial. Thirty-one percent (n  32) developed hyponatremia,
and 25% (n 26) developed renal insufficiency. Only 2% of
our patients, compared with 10% in the RALES study,
developed gynecomastia. Seven percent (n  7/104) of our
patients developed hypotension and 3% (n  3/104) re-
quired temporary pacemaker insertion for hemodynamically
unstable bradyarrhythmia related to serious hyperkalemia
such as complete heart block, Mobitz type II atrioventric-
ular block, or pauses 3 s. Twenty-one percent of our
patients were subsequently discontinued from spironolac-
tone compared with 8% in the RALES trial.
Provider type. Providers were ranked into five categories
according to their specialty, affiliation and training: aca-
demic staff cardiologist, noncardiology academic staff, med-
ical residents, noncardiology medical staff at community
clinics, and physician’s assistants.
As shown in Figure 1, the staff cardiologists, followed by
the academically affiliated noncardiology staff members and
medical residents, had better profiles in appropriate man-
agement of spironolactone treatment in patients with HF
than did other primary care providers. There was a signif-
icant correlation between provider type rank and appropri-
ate management index, with a correlation coefficient of 0.2
and p value of 0.04.
DISCUSSION
Our study reveals that complications with spironolactone
use in patients with HF are greater in clinical practice than
reported in a rigorous trial. According to our results, part of
the reason is broad use of this medication and lack of
appropriate follow-up of the patients. The relative familiar-
ity of primary care providers with spironolactone for other
indications, as well as the low cost and ease of titration of
this medication, probably make it readily applicable for HF.
However, providers appear to have difficulty adhering to
new indication guidelines and resort to their customary
prescription and management habits.
There were a number of striking differences between the
patterns of use of spironolactone for HF in our hospital and
the RALES trial. Although patients were similar in age,
baseline BP, and etiology of HF, only a small percent of our
patients were in NYHA class III to IV and had documented
low LVEF. The average daily dose of spironolactone pre-
scribed in our cohort far exceeded the dose in the RALES
trial, and more patients in our cohort were continued on
potassium supplements despite the absence of hypokalemia.
Likewise, the clinical and laboratory follow-ups were not as
rigorous as in the RALES trial.
Adverse outcome rates, especially hyperkalemia, exceeded
those reported in the RALES trial for several reasons. First,
the higher angiotensin-converting enzyme inhibitor doses
used in our study, closer to the recommended target doses,
may have resulted in more hyperkalemic complications.
Second, more patients with baseline renal insufficiency were
started on spironolactone, and potassium supplements or
potassium-sparing diuretics were not adjusted. Third, half
of our patients had diabetes and may be prone to hy-
poreninemic hypoaldosteronism and hyperkalemia. These
findings, however, are similar to other studies reporting
life-threatening hyperkalemia during combined therapy
with angiotensin-converting enzyme inhibitors and spi-
ronolactone (8–10). Thus, the long-term safety of combi-
nation therapy in HF with high-dose angiotensin-
converting enzyme inhibitors, digoxin, beta-blockers, and
spironolactone is not well established and needs careful
monitoring.
Figure 1. Differences in appropriate patient selection and management
with spironolactone according to provider type. The providers are ranked as
the staff cardiologist, noncardiology academic staff member, medical
resident, satellite clinic nonacademic internist, and the physician assistant.
Vertical axis represents the % of patients in our cohort adhering to RALES
trial management guidelines for appropriate laboratory follow-up (LAB
F/U) (at four weeks and three and six months), New York Heart
Association (NYHA) class selection (class III to IV), left ventricular
ejection fraction (LVEF) selection (35%), and the mean daily dose (25 to
50 mg/day) for spironolactone use in patients with heart failure.
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According to our study, cardiologists provided more
appropriate care in selection and follow up of patients with
HF on spironolactone. As suggested by this and other
studies (11–13), the sophisticated treatment regimen with
increasing number of medications in HF may require input
or close monitoring of a specialist or multidisciplinary team.
With the results of this study, there was an overall change in
patient management at our hospital. A quality improvement
team was formed providing education and feedback on
spironolactone use in HF, and these patients on discharge
were referred to a HF specialty clinic with a cardiologist.
One of the great challenges of medical research is to
translate findings into clinical practice. Though beta-
blockers have been demonstrated to be beneficial in HF by
numerous large-scale clinical trials (4), and are recom-
mended as standard therapy (7), only 34.6% of our patients
placed on spironolactone were on beta-blockers. ACC/
AHA HF guidelines recommend spironolactone to be
initiated only in selected patients after optimal background
therapy including angiotensin-converting enzyme inhibitors
and beta-blockers (7). Our data demonstrate that physicians
initiate spironolactone before beta-blockers in a significant
number of patients. This likely reflects the greater difficulty
in starting beta-blocker therapy, and the need for frequent
follow-up visits to cautiously titrate the dose. As suggested
by Ghali et al. (6), our results also raise the concern that
high levels of publicity created by media coverage, quoting
only the summary of findings of a study, may have resulted
in early but oversimplified adoption of a sophisticated
treatment strategy.
We conclude that long-term studies are needed, with
further data on safety and efficacy of optimal combination
therapy with spironolactone in HF. High-risk patients on
multiple medications not commonly represented in ran-
domized trials may need to be followed up more closely with
regard to safety and medication interaction.
Reprint requests and correspondence: Dr. A. A. Knowlton,
Cardiovascular Division, TB172, University of California, Davis,
One Shields Avenue, Davis, California 95616. E-mail:
aaknowlton@ucdavis.edu.
REFERENCES
1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. Random-
ized Aldactone Evaluation Study Investigators. N Engl J Med 1999;
341:709–17.
2. Margo KL, Luttermoser G, Shaughnessy AF. Spironolactone in
left-sided heart failure: how does it fit in? Am Fam Physician
2001;64:1393–8.
3. Kermani M, Dua A, Gradman AH. Underutilization and clinical
benefits of angiotensin-converting enzyme inhibitors in patients with
asymptomatic left ventricular dysfunction. Am J Cardiol 2000;86:
644–8.
4. Eichhorn EJ. Experience with beta blockers in heart failure mortality
trials. Clin Cardiol 1999;22 Suppl 5:V21–9.
5. Fielding LP, Grace R, Hittinger R. Limitations of randomised
controlled trials. Br Med J 1995;310:1410.
6. Ghali WA, Cornuz J. Early uptake of research findings after fast-track
publication. Lancet 2000;355:579–80.
7. ACC/AHA Guidelines for the Evaluation and Management of
Chronic Heart Failure in the Adult. Circulation 2001;104:2996–3007.
8. Dutka M, Dzielski T, Wojciechowska J, Heller L, Trybus M.
[Drug-related hyperkalemia resulted from spironolactone and angio-
tensin converting enzyme inhibitors therapy]. Pol Merkuriusz Lek
1999;7:69–70.
9. Berry C, McMurray JJ. Serious adverse events experienced by patients
with chronic heart failure taking spironolactone. Heart 2001;85:E8.
10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-
threatening hyperkalemia during combined therapy with angiotensin-
converting enzyme inhibitors and spironolactone: an analysis of 25
cases. Am J Med 2001;110:438–41.
11. Philbin EF, Weil HF, Erb TA, Jenkins PL. Cardiology or primary
care for heart failure in the community setting: process of care and
clinical outcomes. Chest 1999;116:346–54.
12. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the
efficacy of multidisciplinary care in heart failure outpatients at high risk
of hospital readmission. J Am Coll Cardiol 2002;39:471–80.
13. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients
admitted to the hospital with congestive heart failure: specialty-related
disparities in practice patterns and outcomes. J Am Coll Cardiol
1997;30:733–8.
214 Bozkurt et al. JACC Vol. 41, No. 2, 2003
Spironolactone in HF January 15, 2003:211–4
